Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients

Hypertension Research

Volumn 26, Issue 4, 2003, Pages 273-280

  Minami, Mayumi ^a   Atarashi, Keiichiro ^a   Ishiyama, Akihiro ^a   Hirata, Yasunobu ^a   Goto, Atsuo ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cholesterol lowering therapy; Hypercholesterolemia; Nitric oxide; Platelet intracellular Ca2+ concentration; Pressor hyperreactivity

Indexed keywords

CALCIUM ION; CYCLIC GMP; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERTENSIVE FACTOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; NITROGEN OXIDE; PRAVASTATIN;

ADULT; ARITHMETIC; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CALCIUM CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; HAND GRIP; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; MENTAL STRESS; MENTAL TEST; PRESSOR RESPONSE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION;

ANTICHOLESTEREMIC AGENTS; BLOOD PLATELETS; BLOOD PRESSURE; CALCIUM; CATECHOLAMINES; CYCLIC GMP; FEMALE; HAND STRENGTH; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDES; LIPIDS; MALE; MIDDLE AGED; NITRIC OXIDE; PRAVASTATIN; STRESS, PSYCHOLOGICAL;

EID: 0037986830     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.273     Document Type: Article

References (40)

1. Stamler J, Westworth D, Neaton JD: Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Am J Med 1986; 80 (Suppl 2A): 33-39.
2. Laurenzi M, Mancini M, Menotti A, et al, on behalf of the Gubbio Study Group: Multiple risk factors in hypertension: results from the Gubbio Study. J Hypertens 1990; 8 (Suppl 201): S7-S12.
3. Sachinidis A, Mengden T, Locher R, Brunner C, Vetter W: Novel cellular activities for low density lipoprotein in vascular smooth muscle cells. Hypertension 1990; 15: 704-711.
4. Block LK, Knorr M, Vogt E, et al: Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci USA 1988; 85: 885-889.
5. Chowienczyk PJ, Watts GF, Cockroft JR, Ritter JM: Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 1430-1432.
6. Egashira K, Hirooka K, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
7. Sung BH, Izzo JL Jr, Wilson MF: Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens 1997; 10: 592-599.
8. Minami M, Atarashi K, Ishiyama A, et al: Pressor hyperreactivity to mental and hand-grip stresses in patients with hypercholesterolemia. J Hypertens 1999; 17: 185-192.
9. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470-475.
10. Sullivan DR, Kruijswijk Z, West CE, Kohlmeier M, Katan MB: Determination of serum triglycerides by an enzymatic method not affected by free glycerol. Clin Chem 1985; 31: 1227-1228.
11. Brustein M, Scholnick HR, Morfin R: Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 2: 583-595.
12. Friedewald WT, Levy RJ, Frederickson DS: Estimation of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem Acta 1972; 18: 499-502.
13. Ohnishi N, Ohkawa H, Miike A, Tatano T, Yagi K: A new method for lipid peroxides using a methylene blue derivative. Biochem Int 1985; 10: 205-211.
14. Fotl A, Kimura S, DeQuattro V, Lee D: Liquid-chromatographic measurement of catecholamines and metabolites in plasma and urine. Clin Chem 1987; 33: 2209-2213.
15. Hama N, Nakao K, Mukaiyama M, et al: Fundamental and clinical evaluation of 'Shionoria ANP,' human natriuretic peptide IRMA kit. Clin Rep 1991; 25: 4205-4212.
16. 2+ in individual small cells using fluorescence microscopy with dual excitation wavelength. Cell Calcium 1985; 6: 145-157.
17. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
18. 15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
19. Brooker G, Harper JF, Terasaki WL, Moylan RD: Radioimmunoassay for cyclic GMP and cyclic AMP. Adv Cyclic Nucleotide Res 1979; 10: 1-33.
20. Goode GK, Miller J, Haegerty AM: Hyperlipidemia, hypertension, and coronary diseases. Lancet 1995; 345: 362-364.
21. Spósito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JAF: Additional reduction in blood pressure after cholesterol-lowering treatment by statin (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-1499.
22. Kjeldsen SE, Rostup M, Mundel HH, Gjesdal K, Eide IK: The sympathetic nervous system may modulate the metabolic cardiovascular syndrome in essential hypertension. J Cardiovasc Pharmacol 1992; 20: (Suppl 8): S32-S39.
23. Grossman E, Oran S, Garavaglia GE, Schmieder R, Messerli FH: Disparate hemodynamic and sympathoadrenergic responses to isotonic and mental stress in essential hypertension. Am J Cardiol 1989; 64: 42-44.
24. Gleason MM, Medow MS, Tulenko TN: Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res 1991; 69: 216-227.
25. 2+ mobilization in platelets of healthy subjects and in patients with familial hyperlipidemia type II. Thromb Res 1991; 61: 403-409.
26. Knorr M, Locher R, Vogt W, et al: Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Eur J Biochem 1988; 172: 753-759.
27. Zeiher AM, Drexier H, Saurbier B, Just H: Endothelium-mediated coronary blood flow modulation in human: effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 1993; 92: 652-662.
28. Kuo L, Davis MJ, Cannon MS, Chilian WM: Pathophysiological consequences of athrosclerosis extend into the coronary microcirculation: restoration of endothelium-dependent responses by L-arginine. Circ Res 1992; 70: 465-476.
29. Stroes ESG, Koomans HA, deBruin TWA, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
30. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-2551.
31. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the rennin-angiotensin system. Circulation 1999; 99: 2027-2033.
32. Mügge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991; 69: 1293-1300.
33. Mügge A, Elwell JH, Peterson TE, Harrison DG: Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol 1991; 260: C219-C225.
34. Guzik TJ, West NEJ, Black E, et al: Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86: 1008.
35. Chen H, Ikeda Y, Shimpo M, Shimada K: Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res 2000; 23: 187-192.
36. Wassman S, Laufs U, Bäumer AT, et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.
37. 2+ responses in rat A10 vascular smooth muscle cells. Circ Res 1994; 74: 173-181.
38. Egashira K, Ni W, Inoue S, et al: Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res 2000; 23: 353-358.
39. Williams JK, Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-691.
40. Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG: Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995; 92: 898-903.